Bryant Furlow | Authors

Articles

Apalutamide Survival Benefits Unclear for Castration-Resistant Prostate Cancer

October 03, 2019

Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.